Advances in Parasite Vaccines

Dear Colleagues,

Several Parasites lives on or in the human or other animal hosts and cause many serious diseases. In humans, the three main classes of disease-causing parasites are protozoa, helminths, and ectoparasites. Among Protozoan parasites, malaria, caused by the Plasmodium parasite, remains one of the most significant public health problems. The infection is caused by the bite of the Anopheles mosquito, which inoculates the Plasmodium sporozoite into the host skin. In 2018, malaria accounted for an estimated 228 million cases and a total of 405,000 deaths worldwide. The malaria vaccine can save countless lives, help in eliminating poverty from sub-Saharan Africa with improved health systems, and completely eradicate the biggest scourge of humankind forever. In the last few decades, global efforts have helped in the development of the first malaria vaccine, with more candidates in clinical trials and early-development phases. However, the complex life cycle of Plasmodium poses a challenge to malaria vaccine development. Partially effective vaccines may not completely eliminate malaria; however, they might prove useful in combination with existing control strategies. The elimination of parasite diseases such as malaria will probably ultimately depend on the development of combining multiple vaccines with the partial efficacy of targeting different stages of infection. To discuss recent advances in the vaccine against various parasitic disease including malaria, , leishmania, Toxoplasmosis, trypanosomiasis, babesiosis, chagas disease, and others parasitic diseases, I am inviting you to contribute to a Special Issue of Vaccines titled “Advances in Parasite Vaccines”. The issue will also encompass studies underlying immunity to the parasites that cause these diseases. This Special Issue will feature articles related to parasite vaccines, adjuvants, systems immunology, structural vaccinology, computational tools and new approaches, and nanoparticle- and host-directed therapy to boost vaccine efficacy. 

Dr. Gunjan Arora
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.